Author's answer: biosimilar therapy for inflammatory bowel disease

Author's answer: biosimilar therapy for inflammatory bowel disease

Bibliographic Details
Main Authors:	Federico Argüelles-Arias, Manuel Barreiro-de-Acosta, Fernando Carballo, Joaquín Hinojosa, Teresa Tejerina
Format:	Article
Language:	English
Published:	Aran Ediciones 2014-01-01
Series:	Revista Espanola de Enfermedades Digestivas
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082014000100015&lng=en&tlng=en

Similar Items

New contributions to consensus on biosimilars
by: Federico Argüelles-Arias, et al.
Published: (2014-03-01)

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal
by: Federico Argüelles-Arias, et al.
Published: (2013-01-01)

Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease
by: Federico Argüelles-Arias, et al.

Pharmaceutical costs for inflammatory bowel disease units: an issue for department heads? The GESTIONAEII survey
by: Federico Argüelles-Arias, et al.

How is inflammatory bowel disease managed in Spanish gastroenterology departments?: the results of the GESTIONA-EII survey
by: Manuel Barreiro-de-Acosta, et al.

Position statement on the use of biosimilars in inflammatory bowel disease
by: Emanuel Burri, et al.
Published: (2019-12-01)

Current status of biosimilars in the treatment of inflammatory bowel diseases
by: Dong Il Park
Published: (2016-01-01)

BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists
by: Fábio Vieira TEIXEIRA, et al.
Published: (2015-03-01)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020-01-01)

Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico
by: A. Mayoral-Zavala, et al.
Published: (2018-10-01)

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
by: Karoline Soares Garcia, et al.
Published: (2021-05-01)

The importance of the interaction between doctor and patient with inflammatory bowel disease
by: Manuel Barreiro-de-Acosta
Published: (2014-06-01)

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary
by: Richard H. Parrish
Published: (2021-06-01)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
by: Marta Vernero, et al.
Published: (2023-10-01)

Asian Physician’s Perspectives on Biosimilars in Inflammatory Bowel Disease: Are We Ready to Use?
by: Soo-Young Na
Published: (2019-12-01)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
by: Ágnes Milassin, et al.
Published: (2019-04-01)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
by: Rawla P, et al.
Published: (2018-05-01)

Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study
by: María Carmen Fernández-Cano, et al.
Published: (2024-01-01)

Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
by: Valeria Dipasquale, et al.
Published: (2024-02-01)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
by: Valeria Dipasquale, et al.
Published: (2022-03-01)

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
by: Jørgen Jahnsen
Published: (2016-05-01)

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
by: Ferdinando D’Amico, et al.
Published: (2023-10-01)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
by: Zvonimir Petric, et al.
Published: (2022-08-01)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023-10-01)

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
by: Viktoria Bergqvist, et al.
Published: (2018-10-01)

AUTHORS'S ANSWER
by: Leonice Fumiko Sato Kurebayashi, et al.
Published: (2015-08-01)

Down's syndrome and inflammatory bowel disease: is there a real link?
by: Raquel Souto-Rodríguez, et al.

Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017-02-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar
by: Rosanne W. Meijboom, et al.
Published: (2023-09-01)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
by: Jan Marsal, et al.
Published: (2022-06-01)

Clinical Outcomes and Patient Experience of Biosimilar to Biosimilar Infliximab Switching in Patients with Inflammatory Bowel Disease: A Prospective, Single-Centre, Phase IV Interventional Study with a Nested Qualitative Study
by: Clare Harris, et al.
Published: (2023-01-01)

Evolution of the incidence of inflammatory bowel disease in Southern Spain
by: Dina Chaaro-Benallal, et al.

Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities?
by: Baumgart, D, et al.
Published: (2019)

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
by: Daniel C. Baumgart, et al.
Published: (2019-03-01)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
by: Naazish S. Bashir, et al.
Published: (2023-02-01)

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
by: Davide Massimi, et al.
Published: (2021-06-01)

Los biológicos y los biosimilares
by: Carlos Rios Acosta
Published: (2017-06-01)

Cost-effectiveness analysis of ferric carboxymaltose iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
by: Federico Argüelles-Arias, et al.
Published: (2022-05-01)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
by: Uta Kiltz, et al.
Published: (2022-08-01)